Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

The evolutionarily conserved p53 protein and its cellular pathways mediate tumour
suppression through an informed, regulated and integrated set of responses to …

Age-related change in human haematopoiesis causes reduced regenerative capacity,
cytopenias, immune dysfunction and increased risk of blood cancer,–, but the reason for …

BACKGROUND Somatic mutations accumulate in normal tissues as a function of time. The
great majority of these mutations have no effect on fitness, so selection does not act upon …

The implementation of targeted therapies for acute myeloid leukaemia (AML) has been
challenging because of the complex mutational patterns within and across patients as well …

Haematological malignancies were previously thought to be driven solely by genetic or
epigenetic lesions within haematopoietic cells. However, the niches that maintain and …

Cancer is a clonal disorder derived from a single ancestor cell and its progenies that are
positively selected by acquisition of 'driver mutations'. However, the evolution of positively …

Cancer immunotherapy based on genetically redirecting T cells has been used successfully
to treat B cell malignancies,–. In this strategy, the T cell genome is modified by integration of …

Age-related diseases are frequently linked to pathological immune dysfunction, including
excessive inflammation, autoreactivity and immunodeficiency. Recent analyses of human …

Background Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the
presence of an expanded somatic blood-cell clone in persons without other hematologic …